Celia R. Berkers

Celia R. Berkers

Auto-generated profile, based on publicly available information

Celia R. Berkers

Division Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EZEsther A. Zaal
Esther A. Zaal
CBCelia R. Berkers
Celia R. Berkers
Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the treatment of cancers and occurs in virtually every type of anti-cancer therapy. Therefore, understanding how resistance can be prevented, targeted and predicted becomes increasingly important to improve cancer therapy. In the last decade, it has become apparent that alterations in cellular metabolism are a hallmark of cancer cells and that a rewired metabolism is essential for rapid tumor growth and proliferation. Recently, metabolic alterations have been shown to play a role in the sensitivity of cancer cells to widely-used first-line chemotherapeutics. This suggests that metabolic pathways are important mediators of resistance toward anticancer agents. In this review, we highlight the metabolic alterations associated with resistance toward different anticancer agents and discuss how metabolism may be exploited to overcome drug resistance to classical chemotherapy.

5 October 2020 in eLife
Verified
Journal Article
Open access
HJHaojie Jin
Haojie Jin
SWSiying Wang
Siying Wang
EZEsther A Zaal
Esther A Zaal
CWCun Wang
Cun Wang
HWHaiqiu Wu
Haiqiu Wu
RBRené Bernards
René Bernards
The dependency of cancer cells on glutamine may be exploited therapeutically as a new strategy for treating cancers that lack druggable driver genes. Here we found that human liver cancer was dependent on extracellular glutamine. However, targeting glutamine addiction using the glutaminase inhibitor CB-839 as monotherapy had a very limited anticancer effect, even against the most glutamine addicted human liver cancer cells. Using a chemical library, we identified V-9302, a novel inhibitor of glutamine transporter ASCT2, as sensitizing glutamine dependent (GD) cells to CB-839 treatment. Mechanically, a combination of CB-839 and V-9302 depleted glutathione and induced reactive oxygen species (ROS), resulting in apoptosis of GD cells. Moreover, this combination also showed tumor inhibition in HCC xenograft mouse models in vivo. Our findings indicate that dual inhibition of glutamine metabolism by targeting both glutaminase and glutamine transporter ASCT2 represents a potential novel treatment strategy for glutamine addicted liver cancers.

16 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
OBOsnat Bartok
Osnat Bartok
APAbhijeet Pataskar
Abhijeet Pataskar
RNRemco Nagel
Remco Nagel
MLMaarja Laos
Maarja Laos
EGEden Goldfarb
Eden Goldfarb
RAReuven Agami
Reuven Agami

29 August 2017 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
EZEsther A. Zaal
Esther A. Zaal
WWWei Wu
Wei Wu
GJGerrit Jansen
Gerrit Jansen
SZSonja Zweegman
Sonja Zweegman
JCJacqueline Cloos
Jacqueline Cloos
CBCelia R. Berkers
Celia R. Berkers
The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptation to pharmacologically changed environments. Metabolic changes could therefore play an essential role in the development of drug resistance. However, specific metabolic pathways that can be targeted to improve bortezomib therapy remain unidentified. We elucidated the metabolic mechanisms underlying bortezomib resistance by using mass spectrometry-based metabolomics and proteomics on BTZ-sensitive and BTZ–resistant multiple myeloma cell lines as well as in a set of CD138+ cells obtained from multiple myeloma patients. Our findings demonstrate that a rewired glucose metabolism sustains bortezomib resistance. Mechanistically, this results in higher activity of both the pentose phosphate pathway and serine synthesis pathway, ultimately leading to an increased anti-oxidant capacity of BTZ-resistant cells. Moreover, our results link both serine synthesis pathway activity and expression of 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the rate-limiting step of serine synthesis, to bortezomib resistance across different BTZ-resistant multiple myeloma cell lines. Consistently, serine starvation enhanced the cytotoxicity of bortezomib, underscoring the importance of serine metabolism in the response to BTZ. Importantly, in CD138+ cells of clinically bortezomib refractory multiple myeloma patients, PHGDH expression was also markedly increased. Our findings indicate that interfering with serine metabolism may be a novel strategy to improve bortezomib therapy and identify PHGDH as a potential biomarker for BTZ resistance.

1 June 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
YLYves Leestemaker
Yves Leestemaker
AJAnnemieke de Jong
Annemieke de Jong
KWKatharina F. Witting
Katharina F. Witting
RPRenske Penning
Renske Penning
KSKarianne Schuurman
Karianne Schuurman
HOHuib Ovaa
Huib Ovaa

21 September 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SKSander de Kivit
Sander de Kivit
MMMark Mensink
Mark Mensink
AHAnna T. Hoekstra
Anna T. Hoekstra
IBIlana Berlin
Ilana Berlin
RDRico J. E. Derks
Rico J. E. Derks
JBJannie Borst
Jannie Borst